Inclusion Criteria:  No chemoradiotherapy or other anti-tumor therapy before clinical trial performed; Aged 18-75 years; Male or non-pregnant or lactating women; Pathological diagnosis of colorectal adenocarcinoma; Clinical diagnosis of T3 stage or above without distant metastasis and can be given radical surgery (AJCC Version 8, 2018); Normal function of major organs;  Routine blood examinations meeting the following criteria:  A. HB ≥ 90 g/L; B. ANC ≥ 1.5 x 10 9 /L; C. PLT ≥ 125 × 10 9 /L;  Chemistry indexs meeting the following criteria:  A. TBIL < 1.5ULN; B. ALT and AST < 2.5ULN; ALB > 30 g/L C. serum Cr ≤ 1.25 ULN or endogenous creatinine clearance > 50 ml/min (Cockcroft-Gault formula);  ECOG score 0-1;  Exclusion Criteria:  A history of other malignant tumors within 5 years; Distant metastasis found during surgery; Allergic to paclitaxel, lobaplatin and other related chemotherapeutic drugs; Suffering from epilepsy or other mental illness, unable to control behavior; Inability to tolerate surgery due to severe cardiac, pulmonary and vascular disease; Pregnant or lactating women. Receiving anti-cancer drug therapy from other clinical trials.